TRADING UPDATES: MaxCyte inks deal with Be Bio; Orcadian firms farmout
2nd Apr 2024 15:19
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Net loss widens to USD37.9 million in 2023 from USD23.6 million in 2022, as revenue declines by 6.7% to USD41.3 million from 44.3 million. Core business revenue falls by 25% to USD29.8 million from USD39.6 million, but strategic platform license programme-related revenue more than doubles to USD11.5 million from USD4.6 million. In the fourth quarter alone, revenue is USD15.7 million, up 26% from USD12.4 million a year before, as core business revenue falls by 32% but SPL revenue more than quadruples. Read More
(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
MaxCyte Inc - Maryland, US-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Signs strategic platform licence with Wugen Inc, a US-based clinical-stage biotech company developing off-the-shelf cell therapies for the treatment of hematological and solid cancer tumour malignancies. Wugen's lead program is evaluating WU-CART-007, a cell therapy for the treatment of relapsed or refractory T-cell acute lymphoblastic leukaemia. Under the terms of the agreement, Wugen gains non-exclusive clinical and commercial rights to use MaxCyte's unique Flow electroporation technology and its trademarked ExPERT research platform. In exchange, MaxCyte will receive annual licence fees and programme-related revenue, although precise transaction details were not provided. Read More
MaxCyte Inc - Maryland, US-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Announces departure of Cenk Sumen as chief scientific officer, but he will remain on advisory board. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - MaxCyte Inc on Tuesday said that promising returns from its strategic platform licence program had bolstered its quarterly revenue expectations. Read More
(Alliance News) - MaxCyte Inc on Wednesday said it had signed a strategic platform licence with Lion TCR to promote the latter's T cell receptor-T cell pipeline. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday. Read More
(Alliance News) - MaxCyte Inc on Thursday said it expects revenue in the third quarter and for all of 2023 to fall from a year before, citing volatility in customer activity in the life science tools sector. Read More
(Alliance News) - MaxCyte Inc on Thursday reported an increased loss in the first half of 2023, as revenue fell while costs increased. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - MaxCyte Inc on Monday said it signed a strategic platform licence with Vittoria Biotherapeutics to advance cellular therapies. Read More
(Alliance News) - MaxCyte Inc on Thursday said it has signed a strategic platform license with Lyell Immunopharma Inc, a clinical stage T cell reprogramming company. Read More
(Alliance News) - MaxCyte Inc on Thursday reported a widened operating loss in the first quarter of 2023 as revenue fell and costs were higher. Read More